Silicon photonic startup Indigo Diabetes NV has closed a €7 million ($7.4 million) round of series A investment to support its development of an optical glucose monitor for diabetics. Single-chip glucose sensor. Courtesy of Indigo Diabetes NV. The company aims to use research from Ghent University and the imec electronics development center to replace conventional finger-prick blood tests with an implantable optical device. “Licensing a series of new technologies from globally recognized research institutions UGent and imec enables Indigo to enter the market with the first needle-free and calibration-free glucose sensor,” said Danaë Delbeke, founder of Indigo and member of the Photonics Research Group at Ghent. Thuja Capital is the lead investor.